Restricted accessOtherFirst published online 2004-1
Practice Guidelines for the Management of Febrile Infants Less Than 90 Days of Age at the Ambulatory Network of a Large Pediatric Health Care System in the United States: Summary of New Evidence
Baraff LJ, Bass JW, Fleisher GR, et al.Practice guidelines for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med. 1993;22:1198-1210.
2.
Bjornson G, Scheifele DW, Halperin SA, et al.Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. Pediatr Infect Dis J. 2002;21:947-950.
3.
Alpern ER, Alessandrini E, McGowan KL, et al.Serotype prevalence of occult pneumococcal bacteremia. Pediatrics. 2001;108:e23.
4.
Lee GM, Harper MB. Risk of bacteremia in febrile young children in the post-Hemophilus influenzae type b era. Arch Pediatr Adolesc Med. 1998;152:624-628.
5.
Dagan R, Powell KR, Hall KB, et al.Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis. J Pediatr. 1985;107:855-860.
6.
Baker MD, Bell LM, Avner JR. Outpatient management of febrile infants 28 to 90 days of age with intramuscular administration of ceftriaxone. N Engl J Med. 1993;329:1437-1441.
7.
Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. Pediatrics. 1999;103:727-731.
8.
DeAngelis C, Jaffe A, Wilson M, et al.Iatrogenic risks and financial costs of hospitalizing febrile infants. Am J Dis Child. 1983;137:1146-1149.
9.
Baraff LJ. Management of fever without source in infants and children. Ann Emerg Med. 2000;36:602-614.
10.
Jaffe DM, Fleisher GR. Temperature and total white blood cell count as indicators of bacteremia. Pediatrics. 1991;87:670-674.
11.
Whitney CG. The potential of pneumococcal conjugate vaccines for children. Pediatr Infect Dis J. 2002;21:961-970.
12.
Black SB, Shinefield HR, Hansen J, et al.Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2001;20:1105-1107.
13.
Jaskiewicz JA, McCarthy CA, Richardson AC, et al.Febrile infants at low risk for serious bacterial infection—an appraisal of the Rochester criteria and implications for management. Pediatrics. 1994;94:390-396.
14.
Prober CG. Managing the febrile infant: no rules are golden. Contemp Pediatr. 1998;16:48-51.
15.
Yamamoto LG. Revising the decision analysis for febrile children at risk for occult bacteremia in a future era of widespread pneumococcal immunization. Clin Pediatr. 2001;40:583-594.
16.
Klein JO. Management of the febrile child without a focus of infection in the era of universal pneumococcal immunization. Pediatr Infect Dis J. 2002;21:584-588.
17.
Radetsky M. The febrile infant and the assumption of risk. Curr Opin Infect Dis. 1996;9:171-175.
18.
Belfer RA, Gittelman MA, Muniz AE. Management of febrile infants and children by pediatric emergency medicine and emergency medicine: comparison with practice guidelines. Pediatr Emerg Care. 2001;17:83-87.
19.
Young PC. The management of febrile infants by primary care pediatricians in Utah: comparison with published practice guidelines. Pediatrics. 1995;95:623-627.
20.
American Academy of Pediatrics. PROS febrile infants study: final report and appendices. AAP National technical information service report. NOP B2000100683, 2000.
21.
Pulliam PN, Attia M, Cronan K. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. Pediatrics. 2001;108:1275-1279.
22.
Peltola H, Jaakkola M. C-reactive protein in early detection of bacteremic versus viral infections in immunocompetent and compromised hosts. J Pediatr. 1988;113:641-646.
23.
Lacour AG, Gervais A, Zamora SA, et al.Procalcitonin, IL-6, IL-8, Il-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localizing signs. Eur J Pediatr. 2001;160:95-100.
24.
Isaacman D, Burke BL. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. Archiv Pediatr Adolesc Med. 2002;156:905-909.
25.
Gabay CE, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
